SCHEMBL17612283

SCHEMBL17612283

Cc1ncnc2c1ncn2[C@H]1O[C@H]2CO[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)O[C@H]2C1O

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 4/20 0.45
▸ PDE4A P27815 6/20 0.44
▸ PDE4B Q07343 6/20 0.44
▸ PDE4C Q08493 6/20 0.44
▸ PDE4D Q08499 6/20 0.44
▸ LMNA P02545 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ RAPGEF3 O95398 2/20 0.44
▸ GMNN O75496 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ RAPGEF4 Q8WZA2 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ RXFP1 Q9HBX9 2/20 0.43
▸ AHCY P23526 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29674371 0.90 STING1 (0.56) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL16271105 0.90 STING1 (0.56) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL14946346 0.90 STING1 (0.56) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL22983991 0.90 STING1 (0.56) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL17889822 0.90 PDE4A (0.56) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL23813544 0.90 STING1 (0.56) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL9964279 0.90 STING1 (0.56) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL6895355 0.90 STING1 (0.56) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL1801703 0.90 PDE4A (0.56) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL29792990 0.90 PDE4A (0.56) STING1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9290533-B2 β-L-2′-deoxy-nucleosides for the treatment of hepatitis B NOVARTIS AG (CH) 2016-03-22 — — US disclosed
Send feedback